MX363403B - Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. - Google Patents
Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.Info
- Publication number
- MX363403B MX363403B MX2015016389A MX2015016389A MX363403B MX 363403 B MX363403 B MX 363403B MX 2015016389 A MX2015016389 A MX 2015016389A MX 2015016389 A MX2015016389 A MX 2015016389A MX 363403 B MX363403 B MX 363403B
- Authority
- MX
- Mexico
- Prior art keywords
- drug antibody
- tracer
- capture
- immunoassay
- suppressed
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13175091 | 2013-07-04 | ||
| PCT/EP2014/063891 WO2015000865A1 (en) | 2013-07-04 | 2014-07-01 | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015016389A MX2015016389A (es) | 2016-04-11 |
| MX363403B true MX363403B (es) | 2019-03-22 |
Family
ID=48703341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016389A MX363403B (es) | 2013-07-04 | 2014-07-01 | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10168326B2 (https=) |
| EP (1) | EP3017303B1 (https=) |
| JP (2) | JP6563910B2 (https=) |
| KR (1) | KR102248581B1 (https=) |
| CN (1) | CN105378480B (https=) |
| BR (1) | BR112015032960B1 (https=) |
| CA (1) | CA2913687C (https=) |
| MX (1) | MX363403B (https=) |
| RU (1) | RU2674996C2 (https=) |
| WO (1) | WO2015000865A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| SI2493922T1 (sl) | 2009-10-26 | 2017-06-30 | F. Hoffmann-La Roche Ag | Postopek za proizvodnjo glikoziliranega imunoglobulina |
| KR20190120439A (ko) | 2010-11-08 | 2019-10-23 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| WO2015123315A1 (en) * | 2014-02-11 | 2015-08-20 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| JP6889160B2 (ja) * | 2015-12-16 | 2021-06-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ３段階酸解離酵素結合免疫吸着（ｔａｄｅｌｉｓ）アッセイ法 |
| EP3592367B1 (en) * | 2017-03-07 | 2025-04-23 | Roche Diagnostics GmbH | Stable formulations for immune-modulatory macrolides |
| WO2019030202A1 (en) * | 2017-08-08 | 2019-02-14 | F. Hoffmann-La Roche Ag | METHOD FOR DETECTION OF ANTI-MEDICATION ANTIBODIES IN A MINI-PORK SAMPLE |
| MX2020004921A (es) * | 2017-11-29 | 2020-08-27 | Hoffmann La Roche | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo. |
| AU2019301614B2 (en) | 2018-07-10 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods for mitigating drug target interference in an anti-drug antibody (ADA) immunoassay |
| WO2020229378A1 (en) * | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
| EP4085251B1 (en) * | 2020-01-02 | 2024-07-31 | F. Hoffmann-La Roche AG | Method for determining the amount of a therapeutic antibody in the brain |
| CN113495141A (zh) * | 2020-03-20 | 2021-10-12 | 迈克生物股份有限公司 | 2019新型冠状病毒IgM抗体检测试剂盒 |
| KR102934248B1 (ko) | 2020-05-18 | 2026-03-04 | 바이오션, 인코포레이티드 | Il6r에 결합하는 항체 및 이의 용도 |
| KR102626197B1 (ko) * | 2020-11-19 | 2024-01-18 | 바디텍메드(주) | 항 약물 항체의 수준을 정확하게 정량화하는 방법 |
| JP7062803B1 (ja) | 2021-03-31 | 2022-05-06 | 積水メディカル株式会社 | 抗薬物抗体測定方法 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| AU2024216670A1 (en) * | 2023-02-07 | 2025-07-31 | F. Hoffmann-La Roche Ag | Method for the detection of anti-aav particle antibodies |
| CN121666535A (zh) * | 2023-04-20 | 2026-03-13 | 赞特里亚公司 | 用于检测针对抗TNFα抗体的抗药物抗体(ADA)的方法 |
| CN120761634B (zh) * | 2025-09-02 | 2025-12-05 | 宁波熙宁检测技术有限公司 | 一种针对多特异性单克隆抗体药物的ada检测方法 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| JPH066054B2 (ja) | 1987-10-15 | 1994-01-26 | 帝人株式会社 | 動物細胞の培養方法 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| US6428979B1 (en) | 1988-01-22 | 2002-08-06 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| ZA898290B (en) | 1988-11-03 | 1991-06-26 | Igen Inc | Electrochemiluminescent assays |
| KR0132666B1 (en) | 1989-03-14 | 1998-04-14 | Hitachi Kk | Method for controlling cultivation conditions for animal cells |
| ES2093017T3 (es) | 1989-07-20 | 1996-12-16 | Tadamitsu Kishimoto | Anticuerpo contra el receptor de la interleuquina-6 humana. |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| US5821121A (en) | 1991-06-24 | 1998-10-13 | Pacific Biomedical Research, Inc. | Hormone-secreting cells maintained in long-term culture |
| JPH08508875A (ja) | 1992-05-01 | 1996-09-24 | 帝人株式会社 | 蛋白分泌細胞の流加回分培養法 |
| EP0567738A3 (en) | 1992-05-01 | 1995-09-06 | American Cyanamid Co | Controlling perfusion rates in continuous bioreactor culture of animal cells |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| JPH07258252A (ja) | 1994-03-16 | 1995-10-09 | Meiji Seika Kaisha Ltd | チアゾール化合物およびその塩 |
| US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| JP3630453B2 (ja) | 1994-09-30 | 2005-03-16 | 中外製薬株式会社 | Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤 |
| CN1306963C (zh) | 1994-10-21 | 2007-03-28 | 岸本忠三 | 用于治疗il－6产生所致疾病的药物组合物 |
| EP0800829B2 (en) | 1994-12-29 | 2012-07-25 | Chugai Seiyaku Kabushiki Kaisha | Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin |
| EP0811384B1 (en) | 1995-02-13 | 2006-06-21 | Chugai Seiyaku Kabushiki Kaisha | Muscle protein decomposition inhibitor containing il-6 receptor antibody |
| US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4224135B2 (ja) | 1995-10-23 | 2009-02-12 | ズィナイス セラピューティックス ピーティーワイ．エルティーディー． | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 |
| US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
| US6692742B1 (en) | 1996-06-27 | 2004-02-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| WO1998041611A1 (en) | 1997-03-20 | 1998-09-24 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
| EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| CN100374159C (zh) | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
| US6537782B1 (en) | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
| ES2276525T3 (es) | 1998-08-24 | 2007-06-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo. |
| US6284453B1 (en) | 1999-09-29 | 2001-09-04 | Steven Anthony Siano | Method for controlling fermentation growth and metabolism |
| AU2001271021A1 (en) | 2000-07-05 | 2002-01-14 | Japan As Represented By Secretary Of Osaka University | Process for producing glycoprotein |
| JP4812228B2 (ja) | 2000-08-10 | 2011-11-09 | 中外製薬株式会社 | 抗体含有溶液の凝集物生成または白濁抑制方法 |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20040242847A1 (en) | 2000-10-20 | 2004-12-02 | Naoshi Fukushima | Degraded agonist antibody |
| PT1356073E (pt) | 2000-10-20 | 2010-02-15 | Bioneer As | Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico |
| CN1259973C (zh) | 2000-10-25 | 2006-06-21 | 中外制药株式会社 | 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂 |
| JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤 |
| AU2000279624A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| WO2002072615A1 (en) | 2001-03-09 | 2002-09-19 | Chugai Seiyaku Kabushiki Kaisha | Method of purifying protein |
| AU2002256005A1 (en) | 2001-03-27 | 2002-10-08 | Smithkline Beecham Corporation | Control of glycoforms in igg |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| AU2002316230A1 (en) | 2001-06-13 | 2002-12-23 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| CA2480059C (en) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
| JP3822137B2 (ja) | 2002-05-20 | 2006-09-13 | 中外製薬株式会社 | 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法 |
| EP3225625A1 (en) | 2002-09-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
| AU2003291254A1 (en) | 2002-11-05 | 2004-06-07 | Mount Sinai School Of Medicine Of New York University ; | Ptpn11 (shp-2) mutations and cancer |
| DE10255508A1 (de) | 2002-11-27 | 2004-06-17 | Forschungszentrum Jülich GmbH | Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen |
| WO2004073741A1 (ja) | 2003-02-24 | 2004-09-02 | Chugai Seiyaku Kabushiki Kaisha | インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤 |
| US20060239927A1 (en) | 2003-03-31 | 2006-10-26 | Kyowa Hakko Kogyo Co., | Drug for airway administration |
| ES2383014T3 (es) | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| EP1623019B2 (en) | 2003-05-15 | 2017-01-25 | Wyeth LLC | Restricted glucose feed for animal cell culture |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| MXPA06003768A (es) | 2003-10-17 | 2006-06-23 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma. |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
| WO2005090405A1 (ja) | 2004-03-24 | 2005-09-29 | Chugai Seiyaku Kabushiki Kaisha | インターロイキン－６受容体に対するヒト型化抗体のサブタイプ |
| TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
| EP1835022B1 (en) | 2005-01-05 | 2015-02-11 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method and utilization of the same |
| WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
| AR058135A1 (es) | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| AU2007208678B2 (en) | 2006-01-27 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for diseases involving choroidal neovascularization |
| JP4902674B2 (ja) | 2006-03-09 | 2012-03-21 | エフ．ホフマン−ラ ロシュ アーゲー | 抗薬物抗体アッセイ法 |
| JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| JP5330829B2 (ja) | 2006-08-04 | 2013-10-30 | 憲弘 西本 | 関節リウマチ患者の治療予後予測方法 |
| TWI434855B (zh) | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
| JP2010095445A (ja) | 2006-12-27 | 2010-04-30 | Tokyo Medical & Dental Univ | Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤 |
| TWI438208B (zh) | 2007-01-23 | 2014-05-21 | 中外製藥股份有限公司 | 抑制慢性排斥反應之藥劑 |
| EP2174667B1 (en) | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
| MX2010003329A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6. |
| RU2490025C2 (ru) | 2007-10-02 | 2013-08-20 | Чугаи Сейяку Кабусики Кайся | Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6 |
| SG185302A1 (en) | 2007-10-15 | 2012-11-29 | Chugai Pharmaceutical Co Ltd | Method for production of antibody |
| CA2709127C (en) | 2007-12-15 | 2013-11-12 | F. Hoffmann-La Roche Ag | Distinguishing assay |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| DE102008005523A1 (de) | 2008-01-23 | 2009-07-30 | Robert Bosch Gmbh | Kraftstoffinjektor |
| JP2011512875A (ja) | 2008-03-11 | 2011-04-28 | ジェネンテック， インコーポレイテッド | 増強されたａｄｃｃ機能を有する抗体 |
| DE102008013899A1 (de) | 2008-03-12 | 2009-09-17 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium |
| CA2728243C (en) | 2008-06-05 | 2020-03-10 | Chugai Seiyaku Kabushiki Kaisha | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| WO2011013786A1 (ja) | 2009-07-31 | 2011-02-03 | Maeda Shin | 癌の転移抑制剤 |
| US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
| SI2493922T1 (sl) | 2009-10-26 | 2017-06-30 | F. Hoffmann-La Roche Ag | Postopek za proizvodnjo glikoziliranega imunoglobulina |
| WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| WO2011149046A1 (ja) | 2010-05-28 | 2011-12-01 | 独立行政法人国立がん研究センター | 膵癌治療剤 |
| WO2011149051A1 (ja) | 2010-05-28 | 2011-12-01 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
| CA2801107A1 (en) | 2010-06-07 | 2011-12-15 | F. Hoffman-La Roche Ag | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| KR20190120439A (ko) * | 2010-11-08 | 2019-10-23 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| HRP20250713T8 (hr) | 2011-09-01 | 2025-10-24 | Chugai Seiyaku Kabushiki Kaisha | Postupak priprave pripravka koji sadrži visoko koncentrirana protutijela ultrafiltriranjem |
-
2014
- 2014-07-01 BR BR112015032960-8A patent/BR112015032960B1/pt active IP Right Grant
- 2014-07-01 CA CA2913687A patent/CA2913687C/en active Active
- 2014-07-01 JP JP2016522572A patent/JP6563910B2/ja active Active
- 2014-07-01 WO PCT/EP2014/063891 patent/WO2015000865A1/en not_active Ceased
- 2014-07-01 EP EP14734471.7A patent/EP3017303B1/en active Active
- 2014-07-01 KR KR1020157037229A patent/KR102248581B1/ko active Active
- 2014-07-01 RU RU2016101730A patent/RU2674996C2/ru active
- 2014-07-01 CN CN201480037364.5A patent/CN105378480B/zh active Active
- 2014-07-01 MX MX2015016389A patent/MX363403B/es unknown
-
2016
- 2016-03-23 US US15/078,140 patent/US10168326B2/en active Active
-
2018
- 2018-11-21 US US16/197,902 patent/US10761091B2/en active Active
-
2019
- 2019-07-25 JP JP2019137030A patent/JP6761085B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10168326B2 (en) | 2019-01-01 |
| KR102248581B1 (ko) | 2021-05-06 |
| JP2016530495A (ja) | 2016-09-29 |
| RU2674996C2 (ru) | 2018-12-14 |
| EP3017303B1 (en) | 2018-01-03 |
| JP2019207246A (ja) | 2019-12-05 |
| CN105378480A (zh) | 2016-03-02 |
| KR20160029034A (ko) | 2016-03-14 |
| JP6761085B2 (ja) | 2020-09-23 |
| RU2016101730A (ru) | 2017-08-09 |
| EP3017303A1 (en) | 2016-05-11 |
| BR112015032960B1 (pt) | 2021-01-05 |
| MX2015016389A (es) | 2016-04-11 |
| US20190094216A1 (en) | 2019-03-28 |
| CA2913687A1 (en) | 2015-01-08 |
| BR112015032960A8 (pt) | 2019-12-31 |
| RU2016101730A3 (https=) | 2018-05-15 |
| CA2913687C (en) | 2022-12-13 |
| HK1217759A1 (zh) | 2017-01-20 |
| WO2015000865A1 (en) | 2015-01-08 |
| US10761091B2 (en) | 2020-09-01 |
| JP6563910B2 (ja) | 2019-08-21 |
| CN105378480B (zh) | 2018-06-12 |
| US20160313322A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX363403B (es) | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. | |
| TW200741203A (en) | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody | |
| AU2018200278B2 (en) | Antibodies to aripiprazole and use thereof | |
| MX2015012823A (es) | Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo. | |
| EA202190237A1 (ru) | Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada) | |
| WO2014138132A3 (en) | Multi-analyte assay | |
| BR112018017336A2 (pt) | método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão | |
| EP3933406A3 (en) | Antibodies to risperidone and use thereof | |
| MX2014010068A (es) | Metodos y sistemas para amplificacion de señal de bioensayos. | |
| BR112015023355A8 (pt) | antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada. | |
| MX2009012048A (es) | Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato. | |
| EA201370030A1 (ru) | Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням | |
| EP4196770A4 (en) | TR-FRET-BASED ASSAY FOR THE DETECTION OF ANTIBODIES IN SEROLOGICAL SAMPLES | |
| NZ603340A (en) | Yeast cell wall components and detection thereof | |
| EP4257976A3 (en) | Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis | |
| EA200700345A1 (ru) | Обогащённое антитело для выявления микобактериальной инфекции, способы применения и диагностические тесты, применяющие такое антитело | |
| RU2014140135A (ru) | Мультиплексный иммунохроматографический способ определения циркулирующих иммунокомплексов | |
| FR2968767B1 (fr) | Procede et coffret pour le diagnostic in vitro du cancer de la prostate | |
| MX2015013364A (es) | Deteccion especifica de anticuerpos de rata en suero de raton. | |
| MY151190A (en) | Method of detecting pork in processed food and detection kit therefor | |
| RU2012127077A (ru) | Методика проведения иммунохроматографического анализа для серодиагностики | |
| JP2015517658A5 (https=) | ||
| MY194325A (en) | Test object detection method, and immunoassay instrument and monoclonal antibody for same | |
| MX2020011249A (es) | Dispositivo microfluidico multiplexado de alto rendimiento para la deteccion confiable de covid-19 mediante ensayos serologicos. | |
| RU2016104707A (ru) | Клон культивируемых гибридных клеток животного mus musculus l. н-24-продуцент моноклональных антител, специфичных к стафилококковому энтеротоксину н (seh) |